TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06708455: Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

Sponsor: Rapa Therapeutics LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 65 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06708455 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06708455 Rescue Dossier →